Table 2.
Characteristics of COVID-19 positive study patients (in-hospital stay).
| Patients, n | n = 387 |
|---|---|
| AKI | 119/387 (30.7%) |
| AKI stage 1 | 74/118 (62.7%) |
| AKI stage 2 | 26/118 (22%) |
| AKI stage 3 | 18/118 (15.2%) |
| Respiratory support: | |
| Low flow oxygen delivery, n | 202/387 (52.2%) |
| High flow oxygen delivery, n | 192/387 (49.6%) |
| Mechanical ventilation, n | 72/387 (18.6%) |
|
Clinical manifestations (and adverse events)
during hospital stay: |
|
| SARS-CoV-2 -related pneumonia, n | 372/387 (96.1%) |
| Anaemia, n | 11/387 (2.8%) |
| Atrial fibrillation, n | 8/387 (2.0%) |
| Haemodialysis, n | 6/387 (1.5%) |
| Ischemic stroke, n | 2/387 (0.05%) |
| Multi-organ failure, n | 10/387 (2.6%) |
| Pleural effusion, n | 3/387 (0.07%) |
| Posterior reversible encephalopathy syndrome (PRES), n | 2/387 (0.05%) |
| Sepsis, n | 67/387 (17.3%) |
| Thrombosis, n | 23/387 (5.9%) |
| Urinary tract infection (UTI), n | 2/387 (0.05%) |
| Concurrent medical therapy: | |
| ACEIs and/or ARBs, n | 140/386 (36.3%) |
| Antibiotics, n | 319/386 (82.6%) |
| Antivirals, n | 147/386 (82.6%) |
| Diuretics, n | 133/386 (34.4%) |
| FANS, non-steroidal anti-inflammatory drugs, n | 87/387 (22.4%) |
| Glucocorticoids, n | 159/385 (41.3%) |
| Heparin, n | 326/386 (84.4%) |
| Hydroxychloroquine, n | 342/385 (88.8%) |